Arctiin

Pharmacology & Research

Arctiin is the glucoside prodrug of arctigenin — the 4’-O-glucoside of the burdock lignan — and a sibling of matairesinol in the burdock dibenzylbutyrolactone lignan complex (distinct from the mammalian enterolignans). The accuracy point that governs the page: arctiin is a prodrug/reservoir. Gut β-glucosidase hydrolyses it to arctigenin, the more-active aglycone, so most systemic activity is arctigenin’s and arctiin itself is directly “less active” — in DSS colitis, arctigenin but not arctiin was the effective constituent. Its own evidence is a handful of preclinical reports; full pharmacology, PK and safety live on the arctigenin page.

1. Anti-inflammatory

Arctiin itself inhibits COX-2 expression via NF-κB pathways in vitro ^{4Reference 4Lee JY · 2011Anti-inflammatory function of arctiin by inhibiting COX-2 expression via NF-κB pathwaysView study →}, but in DSS colitis arctigenin — not arctiin — was the effective constituent ^{2Reference 2Wu X et al. · 2014AnimalArctigenin but not arctiin is the major effective constituent of Arctium lappa fruit for attenuating DSS-induced colonic inflammation in miceView study →}, underscoring that most of the anti-inflammatory signal is the hydrolysis product’s, not the intact glucoside’s.

Gap: cell/rodent only, with no human data, and the direct arctiin evidence is thin while the aglycone outperforms it ^{2,4Reference 2Wu X et al. · 2014AnimalArctigenin but not arctiin is the major effective constituent of Arctium lappa fruit for attenuating DSS-induced colonic inflammation in miceView study →Reference 4Lee JY · 2011Anti-inflammatory function of arctiin by inhibiting COX-2 expression via NF-κB pathwaysView study →}.

2. Anticancer

A 2024 review compiles arctiin’s reported pro-apoptotic, anti-proliferative and cell-cycle effects across cancer cell lines ^{5Reference 52024ReviewAn insight into the anticancer potentials of the lignan arctiin: a comprehensive review of molecular mechanismsView study →}, much of which overlaps mechanisms attributed to arctigenin after deglycosylation.

Gap: in-vitro/animal only, frequently at supraphysiologic concentrations, with no isolate clinical work and effects largely re-attributable to the aglycone ^{5Reference 52024ReviewAn insight into the anticancer potentials of the lignan arctiin: a comprehensive review of molecular mechanismsView study →}.

3. Dermal / UVB-photoprotective

Arctiin induced a UVB-protective effect in human dermal fibroblasts via microRNA-expression changes ^{3Reference 3Knott A et al. · 2014Arctiin induces a UVB-protective effect in human dermal fibroblast cells through microRNA-expression changesView study →} — one of the few genuinely arctiin-specific (not arctigenin-attributed) findings.

Gap: a single in-vitro study in cultured fibroblasts, with no in-vivo skin or topical human data ^{3Reference 3Knott A et al. · 2014Arctiin induces a UVB-protective effect in human dermal fibroblast cells through microRNA-expression changesView study →}.

4. Metabolic

Arctiin enhanced adipose-tissue browning and energy expenditure by activating the adenosine A2A receptor in a preclinical model ^{6Reference 62025Arctiin, a lignan compound, enhances adipose-tissue browning and energy expenditure by activating the adenosine A2A receptorView study →}.

Gap: rodent-only, a single report, with no human metabolic data ^{6Reference 62025Arctiin, a lignan compound, enhances adipose-tissue browning and energy expenditure by activating the adenosine A2A receptorView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Gut β-glucosidase (intestinal bacteria)	hydrolyses arctiin → arctigenin (→ onward metabolites)	defining prodrug PK — the aglycone is the systemic actor
NF-κB → COX-2	suppressed COX-2 expression (in vitro)	anti-inflammatory
DSS colitis model	arctigenin, not arctiin, effective	confirms arctiin is the less-active precursor
microRNA expression (dermal fibroblasts)	UVB-protective response	dermal/photoprotective (in vitro)
Adenosine A2A receptor	↑ adipose browning, energy expenditure (preclinical)	metabolic

Pharmacokinetics

Arctiin is a glucoside prodrug with low intact oral bioavailability. Human intestinal bacteria transform it — via β-glucosidase deglycosylation — to the aglycone arctigenin, and thereafter toward downstream metabolites ^{1Reference 1Xie LH et al. · 2003Transformation of arctiin to estrogenic and antiestrogenic substances by human intestinal bacteriaView study →}. The absorbed, systemically relevant species is therefore arctigenin, not intact arctiin, and conversion depends on gut-microbiota composition. Arctiin is quantifiable alongside arctigenin in Arctii Fructus preparations, and processing (e.g. stir-frying) shifts the arctiin/arctigenin ratio and its pharmacokinetics ^{7Reference 72022A UHPLC-MS/MS method for evaluating the influence of stir-frying on the pharmacokinetics of seven compounds in Arctii FructusView study →}. Full disposition of the active aglycone (extensive first-pass glucuronidation, poor systemic exposure) is covered on the arctigenin page.

Clinical trials

There are no human interventional trials of arctiin. The only burdock-lignan human data are early-phase trials of an arctigenin-rich burdock-seed extract (GBS-01) — a multi-component preparation reported on the arctigenin page — not of arctiin.

Last checked: July 2026.

Toxicity & Safety

Arctiin is a dietary burdock-seed lignan (also in Forsythia fruit) with ordinary dietary exposure and no signal of toxicity at food levels — hence [low]. There is no isolate toxicology in humans, and preclinical work uses it as a benign lignan glucoside. Because arctiin is hydrolysed to arctigenin in vivo, arctigenin’s own cautions (poor bioavailability, theoretical UGT/CYP interactions, phytoestrogenic/antiproliferative activity) are the relevant safety considerations — those are documented on arctigenin, not restated here.

Pregnancy & lactation

Dietary intake fine; avoid the isolated/supplemental compound. Ordinary dietary burdock-seed/Forsythia lignan exposure is not a specific concern, but isolated or supplemental arctiin is not recommended in pregnancy or lactation — it is hydrolysed to arctigenin (a phytoestrogenic, antiproliferative lignan) and there are no human safety data.

Dosage

There is no established therapeutic dose and no isolate trials. Arctiin functions as a prodrug reservoir for arctigenin; relevant exposure comes from burdock-seed (Niu Bang Zi / Arctii Fructus) and Forsythia fruit preparations, with the body converting arctiin to arctigenin at a rate set by individual gut flora. Any figures would be research references, not recommendations.

References